ArticleDiagnostics (Basel, Switzerland)2024
EUS-FNA versus EUS-FNB in Pancreatic Solid Lesions ≤ 15 mm.
Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Clinical Utility of EUS-FNA/FNB for Diagnosis and Grade Assessment in Pancreatic Neuroendocrine Tumors < 20 mm: A Systematic Review and Meta-Analysis.Journal of hepato-biliary-pancreatic sciences · 2026Pooled it
- Multimodal imaging platform for rapid non-destructive evaluation of pancreatic puncture specimens.Journal of biomedical optics · 2026Article
- Pancreatic cancer.Nature reviews. Disease primers · 2026Review
- Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives.Journal of gastroenterology and hepatology · 2026Review
- Integrated pathology and interventional diagnostic approach to a metastatic grade 1 pancreatic neuroendocrine tumour: a clinical vignette of delayed diagnosis in a low-resource setting.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026Article
- Constructing an ultrasound-assisted organoid model for tumor management.Discover oncology · 2025Review
- Endoscopic ultrasound-guided pancreatic core-needle/microforceps biopsy is a valuable diagnostic tool for pancreatic lesions: Experience from a large academic institution.American journal of clinical pathology · 2025Article
- Diagnostic Value of Cytology in Pancreatic Endoscopic Ultrasound-Guided Fine Needle Aspiration: Accuracy in Common Epithelial Pancreatobiliary Tumors and the Role of Cell Block Analysis.Iranian journal of pathology · 2025Article
- The role of rapid on-site evaluation in pancreatic lesion: a systematic review and meta-analysis of randomized control trials.Therapeutic advances in gastroenterology · 2025Article
- Endoscopic Ultrasound-Guided Pancreatic Tissue Sampling: Lesion Assessment, Needles, and Techniques.Medicina (Kaunas, Lithuania) · 2024Review
- Impact of tumor type and size on macroscopic tissue core retrieval in endoscopic ultrasound-guided fine needle biopsy for pancreatic malignancies.BMC gastroenterology · 2024Article
- Mutational profiling of 103 unresectable pancreatic ductal adenocarcinomas using EUS-guided fine-needle biopsy.Endoscopic ultrasoundArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A small tumor size may impact the diagnostic performance of endoscopic ultrasound-guided tissue acquisition (EUS-TA) for diagnosing solid pancreatic lesions (SPLs). We aimed to compare the diagnostic yield of EUS-guided fine-needle aspiration (FNA) and biopsy (FNB) in SPLs with a diameter ≤ 15 mm. Consecutive patients who underwent EUS-TA for SPLs ≤ 15 mm between January 2015 and December 2022 in a tertiary referral center were retrospectively evaluated. The primary endpoint was diagnostic accuracy. The final diagnosis was based on surgical pathology or disease evolution after a minimum follow-up of 6 months. Inadequate samples were all considered false negatives for the study. Secondary outcomes included sample adequacy, factors impacting accuracy, and safety. We included 368 patients (52.4% male; mean age: 60.2 years) who underwent FNA in 72 cases and FNB in 296. The mean size of SPLs was 11.9 ± 2.6 mm. More than three passes were performed in 5.7% and 61.5% of patients in the FNB and FNA groups, respectively (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.